Prudential Financial Inc. lifted its position in Boston Scientific Corporation (NYSE:BSX) by 149.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,762,674 shares of the medical equipment provider’s stock after buying an additional 2,850,630 shares during the quarter. Prudential Financial Inc. owned approximately 0.35% of Boston Scientific Corporation worth $138,928,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BSX. Janus Henderson Group PLC raised its holdings in shares of Boston Scientific Corporation by 22,491.6% in the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock valued at $1,077,270,000 after buying an additional 38,690,577 shares during the period. Jennison Associates LLC raised its holdings in shares of Boston Scientific Corporation by 405.3% in the 2nd quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock valued at $294,921,000 after buying an additional 8,533,655 shares during the period. BlackRock Inc. raised its holdings in shares of Boston Scientific Corporation by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock valued at $2,777,113,000 after buying an additional 4,439,966 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Boston Scientific Corporation by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after buying an additional 3,033,800 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Boston Scientific Corporation by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock valued at $2,596,181,000 after buying an additional 2,522,556 shares during the period. Hedge funds and other institutional investors own 90.45% of the company’s stock.

Several research firms recently issued reports on BSX. Royal Bank Of Canada reiterated a “buy” rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. UBS AG reiterated a “buy” rating and issued a $31.00 price objective (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, July 31st. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, August 9th. Finally, Cowen and Company reissued an “outperform” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Boston Scientific Corporation presently has a consensus rating of “Buy” and a consensus target price of $30.77.

In other news, EVP Timothy A. Pratt sold 10,104 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $27.46, for a total value of $277,455.84. Following the completion of the sale, the executive vice president now directly owns 185,742 shares of the company’s stock, valued at approximately $5,100,475.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy A. Pratt sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the sale, the executive vice president now directly owns 164,681 shares of the company’s stock, valued at $4,647,297.82. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock valued at $14,581,669 over the last three months. Company insiders own 0.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/boston-scientific-corporation-bsx-shares-bought-by-prudential-financial-inc/1685870.html.

Boston Scientific Corporation (NYSE BSX) traded down $0.05 during trading hours on Tuesday, hitting $27.81. The stock had a trading volume of 7,661,464 shares, compared to its average volume of 5,530,000. The firm has a market cap of $38,180.00, a PE ratio of 22.83, a P/E/G ratio of 2.15 and a beta of 0.99. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the firm posted $0.27 EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. research analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.